$NRXP News

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

NRx Pharmaceuticals Completes Three Process Validation Lots Of Preservative Free Ketamine Produced Under Commercial Conditions In Anticipation Of Nov. 10 Generic Drug User Fee Amendments Goal Date

NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine

NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10

Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression

NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

FDA Reclassifies NRx Pharmaceuticals' Ketamine ANDA Amendment To Minor, Setting New Goal Date For November 10, 2026

BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry

NRx Pharma’s GeNeuro Announces Award Of European Patent Entitled Anti HERV K Envelope Antibody And Uses Thereof

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

NRx Pharmaceuticals’ HOPE Therapeutics To Deploy Zeta Surgical's Newly FDA-Cleared Zeta TMS Robotic System, With Clinical Staff Now In Training Ahead Of Deployment In Florida

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

NRx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript

NRX Pharmaceuticals Inc (NRXP) (Q2 2026) Earnings Call Highlights: Advancing Ketamine Pipeline ...